Stocks - Q : Quality | V : Valuation | PT : Price Trend
Funds - P : Performance | Q : Quality
Funds - P : Performance | Q : Quality
BSE: 544350 | NSE: AGARWALEYE | Hospital & Healthcare Services |
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Agarwals Health Care Ltd is a average quality company.
The key valuation ratios of Dr. Agarwals Health Care Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr. Agarwals Health Care Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0% | 0% | 10.5% | -1.1% | 24.3% | 21.5% | 17.8% | - |
| Value Creation Index ⓘ | NA | NA | NA | NA | NA | -0.2 | -1.1 | 0.8 | 0.6 | 0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0 | 531 | 471 | 696 | 1,018 | 1,332 | 1,332 |
| Sales YoY Gr. | - | NA | NA | NA | NA | NA | -11.2% | 47.7% | 46.2% | 30.9% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 0 | -1.2 | -2.8 | 1.6 | 3.9 | 2.3 | 2.6 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | 148.7% | -41.2% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 0 | 0 | 12.1 | 9 | 10.3 | 26.4 | 47.6 | 147.6 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 0 | -23.6 | -57.6 | 32.1 | 92.2 | 63.9 | 83 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 103 | 99.2 | 164 | 233 | 346 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 1.6 | 1.9 | 1.8 | 1.5 | 1.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 41.4% | 30.9% | ||||
| Adj EPS ⓘ | NA | NA | NA | -41.2% | ||||
| BVPSⓘ | NA | NA | 74.6% | 80.5% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 0 | 0 | -9.5 | -26.6 | 16.2 | 21.9 | 6.5 | 2.7 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 23.3 | 16.6 | 26.1 | 26.7 | 27.2 | 26.7 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | -4.3 | -12.8 | 5.4 | 10 | 5.7 | 6.2 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0.7 | 1 | 1.4 | 0.6 | 0.3 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 76 | 65 | 62 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -16 | -12 | -9 | 0 |
Sales growth is growing at healthy rate in last 3 years 41.40%
Debt to equity has declined versus last 3 years average to 0.29
Sales growth is good in last 4 quarters at 14.73%
Return on Equity has declined versus last 3 years average to 2.70%
Net Profit has been subdued in last 3 years 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.8 | 2.6 |
| TTM Sales (₹ Cr.) | 835 | 1,332 |
| BVPS (₹.) ⓘ | 143.4 | 147.6 |
| Reserves (₹ Cr.) ⓘ | 4,499 | 4,632 |
| P/BV ⓘ | 2.61 | 2.54 |
| PE ⓘ | 497.07 | 142.61 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 370.10 / 463.85 |
| All Time Low / High (₹) | 370.10 / 463.85 |
| Market Cap (₹ Cr.) | 11,845 |
| Equity (₹ Cr.) | 31.6 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 42.4 |
| Pledged * | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Sales | 531 | 471 | 696 | 1,018 | 1,332 |
| Operating Expenses ⓘ | 407 | 394 | 514 | 748 | 970 |
| Manufacturing Costs | 153 | 142 | 184 | 290 | 397 |
| Material Costs | 69 | 60 | 84 | 113 | 137 |
| Employee Cost | 112 | 116 | 140 | 190 | 243 |
| Other Costs ⓘ | 74 | 77 | 107 | 155 | 194 |
| Operating Profit ⓘ | 124 | 77 | 182 | 270 | 362 |
| Operating Profit Margin (%) | 23.3% | 16.3% | 26.1% | 26.5% | 27.2% |
| Other Income ⓘ | 13 | 14 | 22 | 18 | 49 |
| Interest ⓘ | 54 | 44 | 49 | 76 | 101 |
| Depreciation ⓘ | 93 | 95 | 98 | 128 | 170 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -11 | -48 | 57 | 84 | 141 |
| Tax ⓘ | 9 | 10 | 14 | -20 | 46 |
| Profit After Tax | -20 | -58 | 43 | 103 | 95 |
| PAT Margin (%) | -3.7% | -12.4% | 6.2% | 10.1% | 7.1% |
| Adjusted EPS (₹) | -1.0 | -2.7 | 1.8 | 4.0 | 3.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 249 | 184 | 212 | 628 | 1,333 | |||||
| Share Capital ⓘ | 7 | 7 | 7 | 8 | 9 | |||||
| Reserves ⓘ | 242 | 177 | 206 | 620 | 1,324 | |||||
| Minority Interest | 18 | 14 | 21 | 30 | 40 | |||||
| Debt | 157 | 178 | 264 | 310 | 325 | |||||
| Long Term Debt | 145 | 168 | 254 | 306 | 310 | |||||
| Short Term Debt | 12 | 10 | 10 | 5 | 15 | |||||
| Trade Payables | 64 | 75 | 89 | 101 | 133 | |||||
| Others Liabilities ⓘ | 252 | 323 | 425 | 701 | 885 | |||||
| Total Liabilities ⓘ | 740 | 774 | 1,012 | 1,770 | 2,716 | |||||
Fixed Assets | ||||||||||
| Gross Block | 738 | 854 | 1,082 | 1,794 | 2,399 | |||||
| Accumulated Depreciation | 188 | 279 | 381 | 501 | 653 | |||||
| Net Fixed Assetsⓘ | 551 | 575 | 701 | 1,293 | 1,746 | |||||
| CWIP ⓘ | 8 | 11 | 28 | 99 | 118 | |||||
| Investmentsⓘ | 1 | 0 | 0 | 34 | 471 | |||||
| Inventories | 33 | 28 | 33 | 36 | 52 | |||||
| Trade Receivables | 52 | 47 | 57 | 76 | 97 | |||||
| Cash Equivalents | 44 | 65 | 117 | 149 | 125 | |||||
| Others Assetsⓘ | 50 | 48 | 76 | 83 | 108 | |||||
| Total Assets ⓘ | 740 | 774 | 1,012 | 1,770 | 2,716 | |||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 103 | 99 | 164 | 233 | 346 |
| PBT ⓘ | -11 | -48 | 57 | 84 | 141 |
| Adjustment ⓘ | 139 | 145 | 138 | 197 | 233 |
| Changes in Working Capital ⓘ | -9 | 10 | -15 | -13 | 5 |
| Tax Paid ⓘ | -16 | -7 | -16 | -35 | -32 |
| Cash Flow From Investing Activity ⓘ | -80 | -37 | -155 | -509 | -914 |
| Capex | -201 | -33 | -70 | -157 | -228 |
| Net Investments | 0 | 0 | -87 | -348 | -684 |
| Others ⓘ | 122 | -3 | 1 | -4 | -2 |
| Cash Flow From Financing Activityⓘ | -73 | -37 | 35 | 303 | 553 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 301 | 640 |
| Net Proceeds from Borrowing ⓘ | 3 | 22 | 0 | 0 | 0 |
| Interest Paid ⓘ | -32 | -19 | -21 | -29 | -32 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | -1 |
| Others ⓘ | -45 | -40 | 56 | 32 | -54 |
| Net Cash Flow ⓘ | -50 | 25 | 44 | 27 | -15 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -7.89 | -26.95 | 21.77 | 24.58 | 9.69 | |||||
| ROCE (%) | 10.53 | -1.09 | 24.26 | 21.51 | 17.77 | |||||
| Asset Turnover Ratio | 0.72 | 0.62 | 0.78 | 0.73 | 0.59 | |||||
| PAT to CFO Conversion(x) | N/A | N/A | 3.81 | 2.26 | 3.64 | Working Capital Days | ||||
| Receivable Days | 36 | 38 | 27 | 24 | 24 | |||||
| Inventory Days | 23 | 24 | 16 | 12 | 12 | |||||
| Payable Days | 340 | 420 | 357 | 306 | 312 | |||||
Dr. Agarwal's Health Care Limited was incorporated at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.
Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. The company had a market share of around 25% of the total eye care service chain market in India during the Financial Year 2024. The company categorizes its Facilities as Primary Facilities [which are non-surgical eye care facilities); Secondary Facilities (which are surgical Facilities); and Tertiary Facilities (which are super-specialty surgical Facilities and include three centres of excellence (COEs)], depending upon the nature of services provided. The company’s business operations are structured as a “hub and spoke” model, which enables it to build a scalable and accessible platform for the continued growth of its business.
The company’s Primary Facilities provide initial eye care diagnosis and clinical investigation services. The Secondary Facilities at its spokes provide select services including cataract surgeries and clinical investigations while its Tertiary Facilities have super-specialty surgical capabilities including retinal, corneal, and refractive surgeries. The company’s COEs, in addition to being Tertiary Facilities, also offer academic programs in ophthalmology and provide continuous training for its doctors, optometrists, and counsellors, among others. Its integrated hub and spoke model enable deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network.
Business area of the company
The company and its subsidiaries/associate are primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc.
Awards and accreditation
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Download APP
